|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02500 VENUS MEDTECH-B
Nominal 
2.340 +0.070 (+3.084%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 470,833 | -4.180% | 491,373 | 406,461 | 415,862 | 276,047 |
| Cost of Sales | (103,087) | 0.899% | (102,168) | (92,463) | (91,518) | (48,767) |
| Gross Profit | 367,746 | -5.514% | 389,205 | 313,998 | 324,344 | 227,280 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (21,441) | -- | 2,210 | (21,972) | (3,185) | 50 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (4,154) | -66.449% | (12,381) | (13,943) | (11,711) | 570 | |
| Profit / (Loss) before Taxation | (740,713) | 0.731% | (735,340) | (1,156,344) | (377,555) | (185,843) | |
| Taxation | 23,340 | 271.419% | 6,284 | 34,302 | 6,161 | 2,975 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,066 | -87.882% | 25,302 | 64,343 | (2,242) | 879 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (714,307) | 1.500% | (703,754) | (1,057,699) | (373,636) | (181,989) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,297 | -77.717% | 28,259 | 9,975 | (47,575) | (30,495) |
| Depreciation & Amortisation | 111,109 | -10.961% | 124,787 | 112,352 | 51,621 | 37,712 |
| Directors' Emoluments | -- | -- | 3,905 | 4,539 | 4,478 | 3,841 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -163.000 | -1.212% | -165.000 | -242.000 | -85.000 | -45.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (1.393) | (1.666) | (1.042) | (0.579) |
| NBV per share ($) | 5.014 | -- | 6.623 | 8.181 | 10.307 | 9.021 |
| Remarks: | Real time quote last updated: 22/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -714,307,000 |
| %Change | 1.500% |
| EPS / (LPS) | RMB -1.630 |
| NBV Per Share (¥) | RMB 5.014 |